News >

Hamid Highlights Use of T-VEC in Melanoma

Caroline Seymour
Published: Tuesday, Jan 15, 2019

Omid Hamid, MD

Omid Hamid, MD
Talimogene laherparepvec (T-VEC; Imlygic) was approved by the FDA in 2015 for the treatment of patients with locally advanced, unresectable melanoma and has since continued to show durable responses and minimal toxicity as a single agent and in combination with checkpoint inhibitors, making it a worthwhile treatment strategy to explore further, explained Omid Hamid, MD.

“Oncolytic viruses have already been approved in China for head and neck cancer. They’re a great way to prime the immune system,” said Hamid, director of Research and Immuno-Oncology at The Angeles Clinic. “They're not checkpoint inhibitors, so you can prime with the virus and boost with a checkpoint [inhibitor]. They've shown very little toxicity. Oncolytic viruses show a significant benefit that warrant future study.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x